Patient group directions (PGDs)

AI Summary

This guidance document from the UK Medicines and Healthcare products Regulatory Agency (MHRA) outlines the regulatory framework for Patient Group Directions (PGDs) under the Human Medicines Regulations 2012. A PGD is a legal mechanism allowing authorized healthcare professionals to supply or administer specific medicines to pre-defined patient groups without a traditional prescription. Unlike specific company inspection reports, this guidance applies broadly to healthcare providers to prevent systemic violations related to unauthorized medicine distribution. To maintain compliance, organizations must ensure that PGDs are developed by a multidisciplinary team including a doctor and pharmacist, and are formally authorized by recognized bodies such as NHS England or local authorities. Required actions for providers include the implementation of rigorous clinical governance, the maintenance of accurate records for every medicine supplied, and the formal naming and training of all staff members operating under the direction. The guidance emphasizes that PGDs should only be used where they enhance patient care without compromising safety. By following these protocols, healthcare organizations ensure they meet legal standards for medicine management, thereby avoiding the risks associated with the unlicensed supply of medication and ensuring high-quality patient outcomes through standardized clinical pathways.